Introduction
Approximately 20-30% of the patients receiving percutaneous coronary intervention (PCI) worldwide have diabetes mellitus and about half of these are insulin treated. Revascularization of patients with diabetes mellitus remains subject to increased risk of adverse events. 1 -4 Diabetic patients are predisposed to more aggressive atherosclerosis and a higher risk for restenosis. These patients generally have smaller vessels and longer lesions and more often receive multiple stents, which are additional predictors of restenosis. 4 -6 Drug-eluting stents (DES) have proven to reduce restenosis 7 -9 but the use of DES in diabetic patients is considered off-label by the US Food and Drug Administration, because adequate numbers of diabetic patients have not been evaluated in clinical trials. 10, 11 Available data on DES indicate higher risk of late stent thrombosis compared with bare metal stents (BMS), 8, 12 and since patients with diabetes have a higher platelet reactivity 13 and a poorer response to P2Y 12 receptor inhibition 14 than non-diabetics, this could theoretically further increase the risk of late stent thrombosis with DES in diabetics. Results from clinical trials in diabetic patients are very limited so far. 15, 16 In a pooled analysis of Cypher stents vs. BMS, the diabetic subcohort indicated increased mortality in the Cypher-treated patients, 17 whereas another pooled analysis of Taxus stents vs.
BMS in diabetic patients showed no difference in mortality or myocardial infarction (MI). 4 The aim of our study was to investigate long-term safety and efficacy of DES vs. BMS in a large cohort of patients with diabetes mellitus included in the national Swedish Coronary Angiography and Angioplasty Registry (SCAAR).
Methods

Study population
The present study included all consecutive patients with diabetes mellitus in Sweden who underwent coronary stenting from 1 January 2003 until 31 December 2006 for whom at least 1 year of follow-up was available by merging with other national registries. The analyses were based on the type of stent implanted at the first recorded procedure. Patients were divided into three separate cohorts for analyses. Due to the substantially different early incidence of death and new MI in patients treated with primary or rescue PCI in acute ST-elevation MI (STEMI), these patients constituted a separate cohort. The remaining patients were divided into those receiving only one stent (one-stent cohort) and those receiving more than one stent (multiple stents cohort). As the primary analysis, patients receiving DES at the initial PCI were compared with those receiving only BMS. In the multiple stents cohort analysis, patients who received at least one DES were assigned to the DES group, regardless if they received a stent of another type at any time.
Patients receiving BMS were assigned to the BMS group.
The SCAAR SCAAR records continuously all consecutive patients from all centres (n ¼ 29) performing coronary angiography and PCI in Sweden. The list of the most important recorded variables is presented in Table 1 and their definitions are in accordance with international recommendations. 18 Information on restenosis has been registered for patients undergoing a subsequent coronary angiography for clinical reasons since 1 March 2004. The long-term follow-up was based on merging the SCAAR database with other national registries based on all Swedish citizens' unique 10-digit personal identification number. Hospital admission for MI (International Classification of Diseases ICD-10, I21, and I22) was obtained from the Swedish Patient Administration Registry, and vital status and date of death were obtained from the National Population registry until 31 December 2007. The local Ethics Committee at the Uppsala University approved the merging of the registers. The contribution of the group of co-authors is outlined in Appendix A.
Statistical analyses
The methodology has previously been described in detail. 19 In short, the baseline characteristics were summarized with medians and interquartile ranges for continuous variables and percentages for discrete variables. The primary outcome was the composite of death or MI until 31 December 2007. Secondary outcomes were death, MI, and restenosis. To allow for the varying length of follow-up depending on inclusion year, outcome was presented as events per 1000 patientyears and statistically evaluated with Cox's survival analysis. To compensate for the non-randomized design in this observational study, propensity score methods 20 were used. The individual propensity scores, defined as the conditional probability of obtaining a DES based on available covariables, were estimated with a multiple logistic regression model. All pre-specified covariables, presented in Table 1 , were included in the respective models. To evaluate the ability of the propensity score to balance the baseline covariables, a standardized mean of each covariate was calculated for the DES group. The standardization was made according to the propensity score distribution (categorized in deciles) in the BMS group. Adjusted RRs were estimated from Cox's regression models where the propensity score and stent group were entered as covariates.
Because the technology to record restenosis in the register was not available until 1 March 2004, the risk of restenosis was evaluated in patients included after this date in the complete sample as well as in subgroups previously described to be at greater risk of restenosis (stent diameter ,3 mm and stent length 20 mm). 21, 22 The number needed to treat with a DES to prevent one additional restenosis was calculated as described by Altman and Andersen. 23 Restenosis was defined as a diameter reduction of .50% in the index stent on any subsequent coronary angiography performed on a clinical indication. Restenosis in the multiple stents cohort was defined as a restenosis in the index stent. Information on duration of dual antiplatelet therapy was not available but ranged between 6 and 12 months for DES patients. All analyses were performed using the statistical programs SPSS version 15.0 and R version 2.7.1.
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Results
Patients' characteristics and stents
During the 4-year study period, 48 892 patients were treated with 86 552 stents at a total of 55 465 PCIs in Sweden and entered into the database. In total, 20.4% (n ¼ 9970) diabetic patients were treated with stents but 260 (2.6%) were excluded due to incomplete data, leaving 9710 for this analysis. Overall, 2066 patients with STEMI were treated with primary or rescue PCI. The remaining 7644 patients were divided into those receiving one stent only (n ¼ 4358) and those receiving more than one stent (i.e. the multiple stents group, n ¼ 3286). 
Continued
Long-term outcome after drug-eluting stents in diabetes mellitus in the BMS group were: 28% Liberté, 10% Express 2, 23% Driver, 13% Multilink Vision, 3% Multilink Zeta, 2% Multilink Pixel, 6% Coroflex, 4% Jostent Flexmaster, 3% Sorin Chrono/Carbostent, and the remaining 8% were 29 different BMS each of which representing ,2% of the overall stent use. Stents included in the DES group were: 33% Cypher, 39% Taxus Express, 21% Taxus Liberté, and 7% Endeavor. For STEMI patients, the baseline characteristics differed even less between the 1357 patients treated with BMS and the 709 patients treated with DES during primary PCI (Appendix B, Table B1 ).
Death and myocardial infarction
During the entire study period with a median of 2.5 (range 1-4) years of follow-up, 989 deaths or MIs occurred in patients receiving only one stent ( Table 2 ). The unadjusted primary combined outcome of death and MI indicated no statistically significant difference between DES and BMS as shown in Figure 1A . In the multiple stents cohort, 866 deaths or MIs occurred. When translated into events per 1000 patient-years, all event rates were generally higher in the multiple stents cohort compared with the one-stent cohort. After adjustment, the primary outcome did not differ significantly between the stent types in the multiple stents cohort [relative risk (RR), 0.88; 95% confidence interval (CI), 0.75-1.04]. In diabetic patients receiving only one stent, there was no statistically significant difference in mortality rate in crude ( Figure 1B ) or adjusted analysis (RR, 1.08; 95% CI, 0.86-1.35) ( Table 2) . Likewise, there was no statistically significant difference in the multiple stents cohort in adjusted mortality (RR, 0.81; 95% CI, 0.65 -1.00).
The crude rate of MI did not differ statistically significantly in the one-stent cohort ( Figure 1C) , or in the multiple stents cohort ( Table 2) . After adjusting for differences in baseline characteristics, MI was statistically significantly less common in DES-treated patients in the one-stent cohort (RR, 0.80; 95% CI, 0.66-0.96) but the difference did not reach statistical difference in the multiple stents cohort (RR, 0.81; 95% CI, 0.65-1.00).
In the STEMI cohort, no difference between crude or adjusted mortality or MI rate was seen in the 1357 patients receiving BMS compared with the 709 treated with DES during primary PCI. For the combined outcome of death or MI, the crude event curve is shown in Figure 1D and the adjusted RR was 0.92 (95% CI, 0.76-1.11). The unadjusted RR for death was 0.93 (95% CI, 0.75-1.15) and the adjusted RR was 0.99 (95% CI, 0.78 - 1.27 
Restenosis and revascularization
During 2004 -06, restenosis was registered in 101 of 1460 BMS (6.9%) compared with 89 of 1661 DES (5.4%) in the one-stent cohort with similar results in the multiple stents cohort ( Table 2 ). In the one-stent BMS group, there were 33 restenoses per 1000 patient-years compared with 25 in the one-stent DES group. Crude restenosis rates in the multiple stents cohort were 54 per 1000 patient-years in the BMS group compared with 25 per 1000 patient-years in the DES group ( Table 2) . After adjusting for differences in clinical, lesion, and stent characteristics at baseline in Cox's regression analyses, the differences in adjusted restenosis rate between DES and BMS were greater with an RR of 0.50 (95% CI, 0.35-0.70) for all patients in the one-stent cohort and an RR of 0.47 (95% CI, 0.33 -0.66) in the multiple stents cohort. The adjusted 1-year restenosis rates for BMS vs. DES were 6.6 vs. 3.0% in the one-stent cohort and 9.4 vs. 4.6% in the multiple stents group. Restenosis was statistically significantly reduced in all subgroups of diabetic patients based on stent diameter, stent length, and both in stable and unstable CAD in the one-stent cohort and all subgroups in the multiple stents cohort ( Table 3) . Numbers needed to treat with DES to avoid one additional restenosis per year with BMS ranged from 11 to 47 lesions in the different subgroups. Number needed to treat with DES was 36 in the one-stent cohort if no adjustment for lesion characteristic was made and 19 in the multiple stents cohort ( Table 3) . Independent of stent type restenosis was statistically significantly associated with a new event of MI (RR, 5.03; 95% CI, 4.25-5.97) in a multivariable analysis.
In the STEMI cohort, the difference in restenosis rate between DES and BMS was not significantly different in the unadjusted analysis (RR, 0.87; 95% CI, 0.54-1.41) or in the adjusted analysis (RR, 1.02; 95% CI, 0.59 -1.79).
There were no differences in new revascularizations between the one-stent and the multiple stents cohorts so the results are presented for the combined population. In the DES group, 769 (19.0%) patients had a new PCI and 106 (2.6%) had coronary artery bypass surgery during the 4 years of follow-up. In the BMS group, the corresponding numbers were 710 (19.7%) and 117 (3.3%), respectively. Among the 1479 patients receiving a second PCI, the median time to re-intervention was 179 days in the DES group and 160 days in the BMS group. In a Cox regression analysis, the DES group had statistically significantly lower adjusted relative rate of any new revascularization both in the one-stent cohort (RR, 0.85; 95% CI, 0.73-0.99) and in the multiple stents cohort (RR, 0.83; 95% CI, 0.72 -0.96).
The differentiation of insulin-and non-insulin-treated diabetes mellitus was not included in the registry until 1 March 2004 and this information was available for 4062 patients only. There was no heterogeneity in results in the two types of diabetes (Appendix B, Table B2 ).
Discussion
The first important finding in our study of the safety and efficacy of DES vs. BMS use in patients with diabetes mellitus was that there was no difference in the combined outcome of death or MI with up to 4 years of follow-up. There was a statistically significant reduction in the secondary outcome of MI in favour of DES treatment. The lower incidence of MI with DES may be caused by the lower restenosis rate. This explanation is supported by a five times higher adjusted RR of MI in patients with restenosis. However, prolonged dual antiplatelet therapy in DES patients may also contribute to this difference. Drug-eluting stents significantly reduced restenosis to half the rate seen with BMS. This was true both in Long-term outcome after drug-eluting stents in diabetes mellitus patients receiving single and multiple stents. However, due to the higher absolute rate of restenosis in patients with multiple stents, the absolute reduction in restenosis rate with DES was most pronounced among these patients. Restenosis was reduced by half with DES both in stable and unstable CAD, whereas no statistically significant reduction of restenosis with DES could be seen in the STEMI group treated with primary PCI, as described in previous studies of primary PCI. 25, 26 With the exception of STEMI patients, the reduction of restenosis in DES-treated diabetic patients compared with BMS was homogenous in all other analysed subgroups, including insulin-and non-insulin-treated diabetes mellitus patients.
Most benefit was noted in stent diameters ,3 mm or stent length .20 mm. This finding is consistent with the BASKET study 27 which included patients with and without diabetes mellitus. In contrast to the results of the BASKET study, 27 DES was also reasonably efficient in shorter and wider stents when only including diabetics not undergoing primary PCI. Our findings confirm the previous findings of the small (n ¼ 160) randomized DIABETES trial 15 showing lower target lesion revascularization with the sirolimus-eluting Cypher stent compared with BMS, and also those of the shorter 15-month Western Denmark Registry in diabetic patients. 16 In contrast to a meta-analysis 17 of only 428 diabetic patients but in agreement with two other meta-analyses 7,8 of 1411 and 3679 patients with diabetes mellitus in the subgroups, we found no difference in mortality between DES and BMS in our entire diabetes population. The Western Denmark Registry study 16 found a lower mortality in DES patients but this was attributed to the subpopulation of STEMI patients, a finding we could not confirm. A recent registry study of diabetic patients from Massachusetts 28 with comparable limitations as our study presented similar results over 3 years, supporting the hypothesis that DES might not only reduce restenosis, but also MI and death in the highrisk group of patients with diabetes mellitus. To confirm this hypothesis, a randomized trial on diabetic patients is warranted. Although randomized trials usually have the limitation that they do not reflect the real world due to inclusion and exclusion criteria, we have the advantage of a large cohort of unselected consecutive patients with diabetes mellitus treated with coronary stenting at all interventional centres in an entire country. By the use of civil registration number and merging with other national health-care registries, we could ensure complete follow-up regarding new events such as MI, new revascularization, or death. On the other hand, registry studies are always subject to selection bias and often there are problems in compensating for differences in clinical characteristics between the studied groups. In order to limit this problem, we aimed to create comparable groups by propensity score adjustment in addition to dividing the patients into groups receiving a single or multiple stents. By analysing STEMI patients separately (STEMI patients usually have a high early mortality and are more often treated with BMS), we avoided a common problem in the interpretation of results from observational registry studies of stents. In the single-stent cohort, it was noted that patient selection was also based on risk criteria for restenosis 29 but this was adjusted for by the propensity score. After adjustment, the DES and BMS groups' baseline characteristics were as well balanced as in randomized trials with no statistically significant differences except for healthcare region, treated vessel, and restenosis as indication. Since the geographical differences accounted for most of the variation in the DES usage, the decision to use DES was in several centres largely based on local policy rather than the patient's characteristics. This reduces selection bias by patient characteristic but opens for differences in outcome related to differences between centres. Even after excluding STEMI patients, the mortality and MI rates were still higher in our real-world study compared with those Long-term outcome after drug-eluting stents in diabetes mellitus observed in randomized trials, 4 indicating a higher risk profile in PCI patients in daily clinical practice. The higher risk profile in registry studies is a possible explanation to the observed decrease in new MI in patients treated with DES compared with BMS-treated patients, a phenomenon not apparent in lower risk patients included in randomized trials. In the subgroup of STEMI patients, we could not observe any difference in death or MI between the stent types. In contrast to our other subgroups, we could not find any reduction in restenosis rate with DES compared with BMS, which is also in contrast to the 12-month result of the HORIZONS AMI; 30 however, subgroup analyses must be interpreted with caution.
Conclusions
There was no difference in the combined outcome of death or MI with up to 4 years of follow-up in patients with diabetes mellitus receiving DES compared with BMS. With the exception of primary PCI in STEMI patients, restenosis was reduced with DES in all studied subgroups of diabetic patients with the greatest benefit in stent diameters ,3 mm or stent lengths .20 mm. Restenosis was associated with a five times higher adjusted RR of MI and a statistically significantly lower incidence of MI was noted in patients receiving one DES vs. one BMS. Despite the 'off-label' categorization by the US Food and Drug Administration, our real-life study shows that DES is safe and effective in reducing clinical restenosis in patients with diabetes mellitus.
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